{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:38:25Z","timestamp":1773787105851,"version":"3.50.1"},"reference-count":85,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Beginning with imatinib and now spanning 6 oral, highly active, and mostly safe agents, the development of specific targeted therapy for patients with chronic myeloid leukemia (CML) has created a new world featuring chronic maintenance chemotherapy for all treated as such, treatment-free remission, and functional cure after prolonged deep remission in a subset. As a result comes a necessary shift in focus from acute to chronic toxicity, increasing attention to patient comorbidities, and critical thinking around specific adverse events such as metabolic, cardiovascular, and cardiopulmonary effects, which vary from agent to agent. This review aims to pull together the state of the art of managing the \u201cC\u201d in CML\u2014a chronic myeloproliferative neoplasm treated at present over many years with oral BCR-ABL-targeted agents in a population whose overall health can be complex and potentially affected by disease and therapy\u2014and determine how we can better manage a highly treatable and increasingly curable cancer.<\/jats:p>","DOI":"10.1182\/hematology.2021000239","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:07:17Z","timestamp":1639138037000},"page":"113-121","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Lifelong TKI therapy: how to manage cardiovascular and other risks"],"prefix":"10.1182","volume":"2021","author":[{"given":"Michael J.","family":"Mauro","sequence":"first","affiliation":[{"name":"Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"1","key":"2021121012063738600_hem2021000239C1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/asheducation-2018.1.177","article-title":"We do still transplant CML, don't we?","volume":"2018","author":"Craddock","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2021121012063738600_hem2021000239C2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021121012063738600_hem2021000239C3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"13","key":"2021121012063738600_hem2021000239C4","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/bloodadvances.2020001772","article-title":"Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission","volume":"4","author":"Rousselot","year":"2020","journal-title":"Blood Adv"},{"key":"2021121012063738600_hem2021000239C5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2021121012063738600_hem2021000239C6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"2021121012063738600_hem2021000239C7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"2021121012063738600_hem2021000239C8","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021121012063738600_hem2021000239C9","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann Hematol"},{"key":"2021121012063738600_hem2021000239C10","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: chronic myeloid leukemia. Accessed 1June2021. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1427."},{"issue":"1","key":"2021121012063738600_hem2021000239C11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019000120","article-title":"Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission","volume":"134","author":"Shanmuganathan","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2021121012063738600_hem2021000239C12","first-page":"e8788","article-title":"Clinical features and outcomes of patients with chronic myeloid leukemia presenting with isolated thrombocytosis: a systematic review and a case from our institution","volume":"12","author":"Findakly","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"2021121012063738600_hem2021000239C13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.16241","article-title":"Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children","volume":"188","author":"Kn\u00f6fler","year":"2020","journal-title":"Br J Haematol"},{"key":"2021121012063738600_hem2021000239C14","doi-asserted-by":"crossref","first-page":"2040620720966120","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations","volume":"11","author":"Abruzzese","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"2021121012063738600_hem2021000239C15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-018-3665-x","article-title":"In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia","volume":"82","author":"Qosa","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"2021121012063738600_hem2021000239C16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"issue":"19","key":"2021121012063738600_hem2021000239C17","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"issue":"21","key":"2021121012063738600_hem2021000239C18","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","article-title":"Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"121","author":"Yilmaz","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"2021121012063738600_hem2021000239C19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","article-title":"Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2021121012063738600_hem2021000239C20","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"2021121012063738600_hem2021000239C21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12902-018-0303-x","article-title":"Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor","volume":"18","author":"G\u00f3mez-S\u00e1mano","year":"2018","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"2021121012063738600_hem2021000239C22","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.leukres.2011.12.011","article-title":"Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index","volume":"36","author":"Breccia","year":"2012","journal-title":"Leuk Res"},{"issue":"32","key":"2021121012063738600_hem2021000239C23","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"2021121012063738600_hem2021000239C24","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2021121012063738600_hem2021000239C25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03007995.2017.1399870","article-title":"Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US","volume":"34","author":"Franklin","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2021121012063738600_hem2021000239C26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"2021121012063738600_hem2021000239C27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"2021121012063738600_hem2021000239C28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/ejh.13608","article-title":"Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy","volume":"106","author":"Cortes","year":"2021","journal-title":"Eur J Haematol"},{"issue":"2","key":"2021121012063738600_hem2021000239C29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"2021121012063738600_hem2021000239C30","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"issue":"44","key":"2021121012063738600_hem2021000239C31","doi-asserted-by":"crossref","first-page":"72311","DOI":"10.18632\/oncotarget.11100","article-title":"Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients","volume":"7","author":"Bocchia","year":"2016","journal-title":"Oncotarget"},{"key":"2021121012063738600_hem2021000239C32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2018.00055","article-title":"The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model","volume":"5","author":"Pouwer","year":"2018","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2021121012063738600_hem2021000239C33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","article-title":"Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells","volume":"60","author":"Gover-Proaktor","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2021121012063738600_hem2021000239C34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.clml.2021.04.014","article-title":"Genetic heterogeneity in chronic myeloid leukemia: how clonal hematopoiesis and clonal evolution may influence prognosis, treatment outcome, and risk of cardiovascular events","volume":"21","author":"Sant'Antonio","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"2021121012063738600_hem2021000239C35","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021121012063738600_hem2021000239C36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"2021121012063738600_hem2021000239C37","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"issue":"20","key":"2021121012063738600_hem2021000239C38","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021121012063738600_hem2021000239C39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50\u200amg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"2021121012063738600_hem2021000239C40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2021121012063738600_hem2021000239C41","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2021121012063738600_hem2021000239C42","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"2021121012063738600_hem2021000239C43","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/PAS.0000000000000488","article-title":"Dasatinib-related follicular hyperplasia: an underrecognized entity with characteristic morphology","volume":"39","author":"Ozawa","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2021121012063738600_hem2021000239C44","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity","volume":"122","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"2021121012063738600_hem2021000239C45","doi-asserted-by":"crossref","first-page":"2000279","DOI":"10.1183\/13993003.00279-2020","article-title":"Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors","volume":"56","author":"Weatherald","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"2021121012063738600_hem2021000239C46","doi-asserted-by":"crossref","first-page":"1700217","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"issue":"22","key":"2021121012063738600_hem2021000239C47","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2021121012063738600_hem2021000239C48","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"2021121012063738600_hem2021000239C49","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2021121012063738600_hem2021000239C50","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 15","key":"2021121012063738600_hem2021000239C51","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2021.39.15_suppl.7000","article-title":"OPTIC primary analysis: a dose-optimization study of 3 starting doses of ponatinib (PON)","volume":"39","author":"Cortes","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021121012063738600_hem2021000239C52","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1200\/JCO.2020.38.15_suppl.7550","article-title":"An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia","volume":"38","author":"Januzzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"24","key":"2021121012063738600_hem2021000239C53","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"2021121012063738600_hem2021000239C54","first-page":"LBA","article-title":"Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with \u22652 tyrosine kinase inhibitors","volume":"136","author":"Hochhaus","year":"2020","journal-title":"Blood"},{"issue":"7647","key":"2021121012063738600_hem2021000239C55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2021121012063738600_hem2021000239C56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12185-015-1893-y","article-title":"Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia","volume":"103","author":"Mendizabal","year":"2016","journal-title":"Int J Hematol"},{"issue":"11","key":"2021121012063738600_hem2021000239C57","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.leukres.2012.07.012","article-title":"Human immunodeficiency virus infection and chronic myeloid leukemia","volume":"36","author":"Patel","year":"2012","journal-title":"Leuk Res"},{"issue":"12","key":"2021121012063738600_hem2021000239C58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2021121012063738600_hem2021000239C59","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"2021121012063738600_hem2021000239C60","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/ajh.24887","article-title":"First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"92","author":"Goldberg","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2021121012063738600_hem2021000239C61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2021121012063738600_hem2021000239C62","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1111\/cas.14580","article-title":"Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor","volume":"111","author":"Ono","year":"2020","journal-title":"Cancer Sci"},{"issue":"4","key":"2021121012063738600_hem2021000239C63","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","article-title":"Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients","volume":"69","author":"Takahashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2021121012063738600_hem2021000239C64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2021121012063738600_hem2021000239C65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.htct.2020.04.009","article-title":"Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring","volume":"43","author":"Seguro","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"3","key":"2021121012063738600_hem2021000239C66","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1358863X20906868","article-title":"Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors","volume":"25","author":"Kondapalli","year":"2020","journal-title":"Vasc Med"},{"issue":"4","key":"2021121012063738600_hem2021000239C67","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"issue":"3","key":"2021121012063738600_hem2021000239C68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10741-020-09926-y","article-title":"Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib","volume":"25","author":"Casavecchia","year":"2020","journal-title":"Heart Fail Rev"},{"issue":"3","key":"2021121012063738600_hem2021000239C69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000501927","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management","volume":"143","author":"Saussele","year":"2020","journal-title":"Acta Haematol"},{"key":"2021121012063738600_hem2021000239C70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"issue":"10","key":"2021121012063738600_hem2021000239C71","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41375-018-0247-1","article-title":"Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?","volume":"32","author":"Aghel","year":"2018","journal-title":"Leukemia"},{"key":"2021121012063738600_hem2021000239C72","unstructured":"Framingham Heart Study. Hard coronary heart disease. Accessed 18October2021. https:\/\/framinghamheartstudy.org\/fhs-risk-functions\/hard-coronary-heart-disease-10-year-risk\/."},{"issue":"6","key":"2021121012063738600_hem2021000239C73","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"2021121012063738600_hem2021000239C74","unstructured":"European Society of Cardiology. Score risk charts: the European cardiovascular disease risk assessment models. Accessed 18October2021. https:\/\/www.escardio.org\/Education\/Practice-Tools\/CVD-prevention-toolbox\/SCORE-Risk-Charts."},{"issue":"5","key":"2021121012063738600_hem2021000239C75","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/leu.2014.342","article-title":"Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia","volume":"29","author":"Rea","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2021121012063738600_hem2021000239C76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"},{"key":"2021121012063738600_hem2021000239C77","first-page":"357","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"issue":"suppl 1","key":"2021121012063738600_hem2021000239C78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-137613","article-title":"Cardiovascular and metabolic risk in patients with chronic myeloid leukemia in chronic phase receiving first-line BCR-ABL1 tyrosine kinase inhibitors in the United States: baseline and six-month follow-up results from a prospective real-world observational study","volume":"136","author":"Mauro","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2021121012063738600_hem2021000239C79","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-OncologyStudy Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2021121012063738600_hem2021000239C80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"2021121012063738600_hem2021000239C81","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"2021121012063738600_hem2021000239C82","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"2021121012063738600_hem2021000239C83","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2021121012063738600_hem2021000239C84","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2021121012063738600_hem2021000239C85","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/113\/1851432\/113mauro.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/113\/1851432\/113mauro.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:08:22Z","timestamp":1639138102000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/113\/482934\/Lifelong-TKI-therapy-how-to-manage-cardiovascular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000239","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}